Robert Frederich
6PUBLICATIONS
25CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Feb 09, 2026
Post-authorization safety study to assess the risk of diabetic ketoacidosis among type 2 diabetes mellitus patients treated with ertugliflozin compared to patients treated with other antihyperglycaemic agents in a Medicare and Medicaid population.Ashish Rai, James Marshall, Sampada Nandyala
|Dec 19, 2024
Long-term weight loss and cardiorenal outcomes by baseline BMI in the VERTIS CV trial.Francesco Cosentino, Samuel Dagogo-Jack, Robert Frederich
|Oct 21, 2023
Ertugliflozin and hospitalization for heart failure across the spectrum of pre-trial ejection fraction: post-hoc analyses of the VERTIS CV trial.Ambarish Pandey, Ahmed A Kolkailah, Francesco Cosentino
|Feb 10, 2023
Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity.Linong Ji, Jie Liu, Zhi Jin Xu
|Jan 03, 2023
Potential for residual cardiovascular risk reduction: Eligibility for icosapent ethyl in the VERTIS CV population with type 2 diabetes and atherosclerotic cardiovascular disease.Joseph M Kim, Deepak L Bhatt, Samuel Dagogo-Jack
Pageof 1
Frequent Collaborators
4 joint publications
Nilo B Cater
3 joint publications
Francesco Cosentino
3 joint publications
Christopher P Cannon
3 joint publications
David Z I Cherney
3 joint publications
Samuel Dagogo-Jack
3 joint publications
Richard E Pratley
2 joint publications
Darren K McGuire
1 joint publications
Ambarish Pandey
1 joint publications
Ahmed A Kolkailah
1 joint publications
Neeta B Amin
